That is funny ! Pearson is a clown, he is the reason the stock has only just started to find a bottom with his ridiculous margin call and his last 2 performances.
Think the short game is about done here.
had to do with Kyle Bass' patent challenge.
USPTO announced Kyle Bass's IPR was accepted for review. In the view of analyst Michael J. Yee of RBC, the first IPR is not relevant. Though investors are still waiting on a second, Yee said he's not too concerns.
Valeant expects full-year earnings in the range of $11.67 to $11.87 per share, with revenue ranging from $11 billion to $11.2 billion.
Looks like a buy to me considering this is still growing excluding any price increases.
and today .... and for who knows how long (which can become bad news if there are only buying opportunity days with no selling opportunity days !!!)
Thanks for the response. As a comparison to CHRS, I have PFNX in the biosimilar space. Happy I did not buy AGIO today, Clinton has certainly created some opportunities for those with cash on the sidelines.
Hey Dr Barney (not being facetious), I see you had a position in AGIO, are you still bullish on it ? i also have a position, thinking about increasing it.
Doom for the shorts. This puppy is going much higher.
perhaps some institutions/investors are starting to understand the value of PTLA ? but that was a lot of volume into the close. Holding tight is what I am doing right now.